Sanctuary Advisors LLC Has $27.19 Million Stock Position in Gilead Sciences, Inc. $GILD

Key Points

• Sanctuary Advisors LLC increased its position in Gilead Sciences by 6.5% in Q4 to 221,511 shares, valued at approximately $27.19 million.
• Insiders sold a combined 178,640 shares over the past 90 days — including CEO Daniel Patrick O'Day's sale of 115,640 shares — totaling roughly $26.7 million, with insiders now owning about 0.30% of the company.
• Gilead beat quarterly expectations (EPS $1.86 vs. $1.83; revenue $7.93B vs. $7.68B), raised its quarterly dividend to $0.82 (annualized $3.28, ~2.5% yield), and provided FY2026 EPS guidance of 8.45–8.85 amid a consensus analyst target near $157.35.

Sanctuary Advisors LLC grew its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 6.5% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 221,511 shares of the biopharmaceutical company's stock after buying an additional 13,569 shares during the period. Sanctuary Advisors LLC's holdings in Gilead Sciences were worth $27,188,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Quent Capital LLC increased its stake in shares of Gilead Sciences by 6.4% in the 4th quarter. Quent Capital LLC now owns 3,818 shares of the biopharmaceutical company's stock valued at $469,000 after buying an additional 229 shares during the period. Advisors Capital Management LLC increased its stake in shares of Gilead Sciences by 0.5% in the 4th quarter. Advisors Capital Management LLC now owns 30,714 shares of the biopharmaceutical company's stock valued at $3,770,000 after buying an additional 147 shares during the period. Brindle & Bay Financial Advisors LLC acquired a new stake in shares of Gilead Sciences in the 4th quarter valued at $742,000. Vanguard Group Inc. increased its stake in shares of Gilead Sciences by 1.8% in the 4th quarter. Vanguard Group Inc. now owns 121,097,336 shares of the biopharmaceutical company's stock valued at $14,863,487,000 after buying an additional 2,113,692 shares during the period. Finally, Munich Reinsurance Co Stock Corp in Munich boosted its position in shares of Gilead Sciences by 8.2% in the 4th quarter. Munich Reinsurance Co Stock Corp in Munich now owns 657,973 shares of the biopharmaceutical company's stock worth $81,049,000 after purchasing an additional 49,868 shares during the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 28,000 shares of the business's stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $154.44, for a total value of $4,324,320.00. Following the completion of the transaction, the insider directly owned 120,288 shares of the company's stock, valued at approximately $18,577,278.72. The trade was a 18.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Daniel Patrick O'day sold 115,640 shares of the business's stock in a transaction dated Thursday, February 5th. The shares were sold at an average price of $150.00, for a total value of $17,346,000.00. Following the completion of the transaction, the chief executive officer directly owned 613,912 shares of the company's stock, valued at approximately $92,086,800. The trade was a 15.85% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 178,640 shares of company stock valued at $26,691,550. Company insiders own 0.30% of the company's stock.

Gilead Sciences Price Performance

NASDAQ:GILD opened at $130.40 on Monday. Gilead Sciences, Inc. has a 1 year low of $93.37 and a 1 year high of $157.29. The company has a current ratio of 1.55, a quick ratio of 1.40 and a debt-to-equity ratio of 0.98. The stock has a market cap of $161.86 billion, a price-to-earnings ratio of 19.26, a PEG ratio of 1.72 and a beta of 0.39. The stock has a 50-day moving average price of $142.44 and a two-hundred day moving average price of $132.22.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.83 by $0.03. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The firm had revenue of $7.93 billion during the quarter, compared to analysts' expectations of $7.68 billion. During the same period in the previous year, the firm earned $1.90 earnings per share. The company's revenue was up 4.7% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. As a group, equities analysts expect that Gilead Sciences, Inc. will post 8.62 earnings per share for the current year.

Gilead Sciences Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, March 30th. Shareholders of record on Friday, March 13th were paid a $0.82 dividend. The ex-dividend date of this dividend was Friday, March 13th. This is a positive change from Gilead Sciences's previous quarterly dividend of $0.79. This represents a $3.28 dividend on an annualized basis and a yield of 2.5%. Gilead Sciences's payout ratio is presently 48.45%.

Analysts Set New Price Targets

Several research analysts have recently issued reports on GILD shares. Royal Bank Of Canada raised their price target on Gilead Sciences from $118.00 to $123.00 and gave the stock a "sector perform" rating in a research report on Tuesday, April 7th. BMO Capital Markets raised their price target on Gilead Sciences from $135.00 to $150.00 and gave the stock an "outperform" rating in a research report on Monday, January 26th. Jefferies Financial Group started coverage on Gilead Sciences in a research report on Tuesday, March 10th. They issued a "buy" rating and a $180.00 price target on the stock. Mizuho raised their price target on Gilead Sciences from $140.00 to $170.00 and gave the stock an "outperform" rating in a research report on Wednesday, February 18th. Finally, Sanford C. Bernstein restated an "outperform" rating and issued a $160.00 price target on shares of Gilead Sciences in a research report on Wednesday, February 11th. Twenty-four investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $157.35.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.